Across TCGA pan-cancer cohorts, LCN10 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LCN10 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher LCN10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCN10 expression acts as an unfavorable survival marker.

PAAD, UCEC, and COAD are the cancer types where LCN10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Median	All	0.068	0.484	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	All	0.160	0.693	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LCN10 tumor-vs-normal RNA expression · all LCN10 data types